ITUA20162575A1 - Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa - Google Patents

Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa

Info

Publication number
ITUA20162575A1
ITUA20162575A1 ITUA2016A002575A ITUA20162575A ITUA20162575A1 IT UA20162575 A1 ITUA20162575 A1 IT UA20162575A1 IT UA2016A002575 A ITUA2016A002575 A IT UA2016A002575A IT UA20162575 A ITUA20162575 A IT UA20162575A IT UA20162575 A1 ITUA20162575 A1 IT UA20162575A1
Authority
IT
Italy
Prior art keywords
diseases
pharmaceutical
treatment
disorders related
polycystic ovary
Prior art date
Application number
ITUA2016A002575A
Other languages
English (en)
Inventor
Bernard Fioretti
Lucio Leonardi
Original Assignee
S&R Farm S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56555565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITUA20162575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S&R Farm S P A filed Critical S&R Farm S P A
Priority to ITUA2016A002575A priority Critical patent/ITUA20162575A1/it
Priority to US16/093,295 priority patent/US11246834B2/en
Priority to EP17727376.0A priority patent/EP3452012B1/en
Priority to PCT/IB2017/052151 priority patent/WO2017179012A1/en
Priority to ES17727376T priority patent/ES2890050T3/es
Priority to HUE17727376A priority patent/HUE055882T2/hu
Priority to PL17727376T priority patent/PL3452012T3/pl
Publication of ITUA20162575A1 publication Critical patent/ITUA20162575A1/it
Priority to US17/583,051 priority patent/US20220395460A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ITUA2016A002575A 2016-04-13 2016-04-13 Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa ITUA20162575A1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ITUA2016A002575A ITUA20162575A1 (it) 2016-04-13 2016-04-13 Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
US16/093,295 US11246834B2 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
EP17727376.0A EP3452012B1 (en) 2016-04-13 2017-04-13 Compositions for treating polycystic ovary syndrome and related metabolic disorders
PCT/IB2017/052151 WO2017179012A1 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
ES17727376T ES2890050T3 (es) 2016-04-13 2017-04-13 Composiciones para tratar el síndrome del ovario poliquístico y trastornos metabólicos relacionados
HUE17727376A HUE055882T2 (hu) 2016-04-13 2017-04-13 Készítmény policisztás ovárium szindróma és ehhez kapcsolódó anyagcserezavarok kezelésére
PL17727376T PL3452012T3 (pl) 2016-04-13 2017-04-13 Kompozycje do leczenia zespołu policystycznych jajników i powiązanych zaburzeń metabolicznych
US17/583,051 US20220395460A1 (en) 2016-04-13 2022-01-24 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A002575A ITUA20162575A1 (it) 2016-04-13 2016-04-13 Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa

Publications (1)

Publication Number Publication Date
ITUA20162575A1 true ITUA20162575A1 (it) 2017-10-13

Family

ID=56555565

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A002575A ITUA20162575A1 (it) 2016-04-13 2016-04-13 Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa

Country Status (7)

Country Link
US (2) US11246834B2 (it)
EP (1) EP3452012B1 (it)
ES (1) ES2890050T3 (it)
HU (1) HUE055882T2 (it)
IT (1) ITUA20162575A1 (it)
PL (1) PL3452012T3 (it)
WO (1) WO2017179012A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
EP3713552A1 (en) 2017-11-23 2020-09-30 Biosearch S.A. Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome
PL238919B1 (pl) * 2018-02-28 2021-10-18 Verco Spolka Akcyjna Kompozycja farmaceutyczna zawierająca mio-inozytol i D-chiro- inozytol, do zastosowania w terapeutycznym sposobie obniżania masy ciała u kobiet z zespołem policystycznych jajników
US12171728B2 (en) 2018-04-16 2024-12-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
IT201800011155A1 (it) * 2018-12-17 2020-06-17 S&R Farm S P A uso di una miscela di berberina e resveratrolo per il controllo delle dislipidemie
WO2021053685A1 (en) * 2019-09-20 2021-03-25 Ramesh Patodia A novel nutraceutical formulation for polycystic ovary syndrome (pcos)
EP4000626A1 (en) * 2020-11-16 2022-05-25 concrete flowers GmbH Pharmaceutical preparation
IT202200025767A1 (it) * 2022-12-15 2024-06-15 Prolabin & Tefarm S R L Formulazione comprendente polifenoli vanilloidi supportati su solidi lamellari per ridurre i livelli plasmatici di CGRP e sue applicazioni.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107905A1 (en) * 2011-02-10 2012-08-16 Paladin Pharma S.P.A. Composition for use in the treatment of menopause problems/disorders and in the treatment of general aging of the organism.
WO2013076121A1 (en) * 2011-11-22 2013-05-30 Lo.Li. Pharma S.R.L. Pharmaceutical composition comprising myo-inositol and d-chiro-inositol
EP2875809A1 (en) * 2013-11-26 2015-05-27 Dicofarm Spa Product based on an association of glucomannan and inositol
IN2014MU01312A (it) * 2014-04-09 2015-10-16 Olive Healthcare

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
US20100129467A9 (en) 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
US8383165B1 (en) 2009-08-31 2013-02-26 Fairhaven Health, Llc Composition and method for fertility therapy using nutritional supplements
US20130224281A1 (en) 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
ITPG20120030A1 (it) 2012-06-27 2013-12-29 Bernard Fioretti Resveratrolo inorganico ibrido
ITUB20153066A1 (it) * 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
US10092545B2 (en) 2016-04-30 2018-10-09 Fairhaven Health, Llc Nutritional supplements for improving female fertility
US12171728B2 (en) 2018-04-16 2024-12-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107905A1 (en) * 2011-02-10 2012-08-16 Paladin Pharma S.P.A. Composition for use in the treatment of menopause problems/disorders and in the treatment of general aging of the organism.
WO2013076121A1 (en) * 2011-11-22 2013-05-30 Lo.Li. Pharma S.R.L. Pharmaceutical composition comprising myo-inositol and d-chiro-inositol
EP2875809A1 (en) * 2013-11-26 2015-05-27 Dicofarm Spa Product based on an association of glucomannan and inositol
IN2014MU01312A (it) * 2014-04-09 2015-10-16 Olive Healthcare

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Female infertility but not only... discover the polycystic ovary syndrome", S&R FARMACEUTICI NL|10 - 28 JUNE 2016, 28 June 2016 (2016-06-28), XP055325540, Retrieved from the Internet <URL:http://www.srfarmaceutici.it/nl10-28-june-2016/?lang=en> [retrieved on 20161202] *
DATABASE EPODOC [online] EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002765077, Database accession no. IN-1312MU2014-A *
DATABASE WPI Week 201601, Derwent World Patents Index; AN 2015-662344, XP002765076 *

Also Published As

Publication number Publication date
US20220395460A1 (en) 2022-12-15
WO2017179012A1 (en) 2017-10-19
ES2890050T3 (es) 2022-01-17
EP3452012A1 (en) 2019-03-13
US11246834B2 (en) 2022-02-15
US20190125675A1 (en) 2019-05-02
PL3452012T3 (pl) 2022-01-24
EP3452012B1 (en) 2021-06-23
HUE055882T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
SV2018005610A (es) Derivados de oxopiridina sustituidos
IL259040A (en) Use of tlr8 agonists to treat cancer
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
HUE059041T2 (hu) Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
LT3655038T (lt) Farmacinė kompozicija
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
PL3452012T3 (pl) Kompozycje do leczenia zespołu policystycznych jajników i powiązanych zaburzeń metabolicznych
UY35746A (es) Derivados de fenilalanina sustituidos
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell&#39;apparato uro-genitale
DK3369429T3 (da) Farmaceutisk sammensætning tiltænkt at blive administreret til næseslimhinden
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
GEAP201814463A (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas